To determine whether ACLY activity is required for PD-1-deficient lymphoma cell survival, we next incubated transformed ITK–SYK+PD-1− T cells from tamoxifen-injected ITK-SYKCD4-CreERT2;Pdcd1−/− mice with an ACLY inhibitor. This evidence concerns the gene ITK and lymphoma.